Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Stopped early · Phase 2

Conditions studied: Advanced Breast Cancer

In brief

This is a phase 2, open-label, multicenter, 2-arm study of bosutinib administered in combination with exemestane versus exemestane alone. This is a 2-part study consisting of a safety lead-in phase and randomized phase 2 portion. Subjects in part 1 will receive bosutinib and exemestane daily, and will be closely monitored for 28 days. If no safety concerns arise, then future eligible subjects will be randomly assigned to the main phase of the study. They will either receive bosutinib daily combined with daily exemestane, or daily exemestane alone for a specified period of time. Subjects will be followed up for survival after treatment discontinuation.

Key facts

Study ID

NCT00793546

Run by

Pfizer

People needed

42

Starts

2009-02-01

Expected to finish

2010-06-01

Last updated by the study team

2012-11-05

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Woman aged 18 years or older.
• Confirmed pathologic diagnosis of breast cancer.
• Locally advanced, metastatic, or locoregional recurrent breast cancer not amenable to curative treatment with surgery or radiotherapy.
• Surgically sterile or postmenopausal woman.
• Documented ER+ and/or PgR+ and erbB2- tumor.
• Progression of locally advanced or metastatic disease during treatment with a nonsteroidal AI or tamoxifen, or progression during treatment with (or within 6 months of discontinuation of) an adjuvant nonsteroidal AI.

You may not qualify if…

• Prior exemestane, prior bosutinib, or any other prior anti-Src therapy.
• More than 1 prior endocrine treatment for locally advanced or MBC.
• More than 1 prior cytotoxic chemotherapy regimen in metastatic setting.
• Bone or skin as the only site of disease.

Where it is running

• Pfizer Investigational Site — Lake Worth, Florida, United States
• Pfizer Investigational Site — Joliet, Illinois, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Detroit, Michigan, United States
• Pfizer Investigational Site — New Brunswick, New Jersey, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Bethlehem, Pennsylvania, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Seattle, Washington, United States
• Pfizer Investigational Site — South Brisbane, Queensland, Australia
• Pfizer Investigational Site — Brussels, Brussels Capital, Belgium
• Pfizer Investigational Site — Leuven, Leuven, Belgium
• Pfizer Investigational Site — Liège, Liege, Belgium
• Pfizer Investigational Site — Wilrijk, Belgium
• Pfizer Investigational Site — Kelowna, British Columbia, Canada
• Pfizer Investigational Site — Beijing, China
• Pfizer Investigational Site — Hong Kong, Hong Kong
• Pfizer Investigational Site — Budapest, Hungary
• Pfizer Investigational Site — Mumbai, Maharashtra, India
• Pfizer Investigational Site — Pune, Maharashtra, India
• Pfizer Investigational Site — Olsztyn, Poland
• Pfizer Investigational Site — Lynnwood, Gauteng, South Africa
• Pfizer Investigational Site — Barcelona, Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.